lobbying_filings_raw: 3de3dc87-c154-4d42-9564-7c81113d280f
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| filing_uuid | filing_type | registrant_id | registrant_name | client_id | client_name | filing_year | filing_period | received_date | is_amendment | is_no_activity | is_termination | raw_json | registrant_state | registrant_country | registrant_house_id | client_state | client_ppb_state | client_country | client_ppb_country | client_general_description | client_government_entity | affiliated_org_count | client_entity_id | client_government_unit_id | client_match_method | client_match_confidence | income_amount | expense_amount |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3de3dc87-c154-4d42-9564-7c81113d280f | Q1 | 400931695 | DESIMONE CONSULTING, LLC | 196261 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | 2021 | first_quarter | 2021-04-17T13:18:59.457000-04:00 | 0 | 0 | 0 | {"url": "https://lda.senate.gov/api/v1/filings/3de3dc87-c154-4d42-9564-7c81113d280f/", "filing_uuid": "3de3dc87-c154-4d42-9564-7c81113d280f", "filing_type": "Q1", "filing_type_display": "1st Quarter - Report", "filing_year": 2021, "filing_period": "first_quarter", "filing_period_display": "1st Quarter (Jan 1 - Mar 31)", "filing_document_url": "https://lda.senate.gov/filings/public/filing/3de3dc87-c154-4d42-9564-7c81113d280f/print/", "filing_document_content_type": "text/html", "income": "60000.00", "expenses": null, "expenses_method": null, "expenses_method_display": null, "posted_by_name": "Rick Desimone", "dt_posted": "2021-04-17T13:18:59.457000-04:00", "termination_date": null, "registrant_country": "United States of America", "registrant_ppb_country": null, "registrant_address_1": "78 Orchard Road North", "registrant_address_2": null, "registrant_different_address": false, "registrant_city": "Tacoma", "registrant_state": "WA", "registrant_zip": "98406", "registrant": {"id": 400931695, "url": "https://lda.senate.gov/api/v1/registrants/400931695/", "house_registrant_id": null, "name": "DESIMONE CONSULTING, LLC", "description": "consulting firm", "address_1": "307 29thStreet NE, Suite 104", "address_2": null, "address_3": null, "address_4": null, "city": "Puyallup", "state": "WA", "state_display": "Washington", "zip": "98372", "country": "US", "country_display": "United States of America", "ppb_country": "US", "ppb_country_display": "United States of America", "contact_name": "RICK DESIMONE", "contact_telephone": "+1 253-441-7275", "dt_updated": "2026-01-28T15:15:42.554551-05:00"}, "client": {"id": 196261, "url": "https://lda.senate.gov/api/v1/clients/196261/", "client_id": 12, "name": "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)", "general_description": "trade group representing U.S. pharmaceutical research and biotechnology companies", "client_government_entity": false, "client_self_select": false, "state": "DC", "state_display": "District of Columbia", "country": "US", "country_display": "United States of America", "ppb_state": null, "ppb_state_display": null, "ppb_country": "US", "ppb_country_display": "United States of America", "effective_date": "2012-02-06"}, "lobbying_activities": [{"general_issue_code": "ECN", "general_issue_code_display": "Economics/Economic Development", "description": "Issues related to the impact of the bio-pharmaceutical industry on the economy.", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 56443, "prefix": null, "prefix_display": null, "first_name": "RICK", "nickname": null, "middle_name": null, "last_name": "DESIMONE", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "MMM", "general_issue_code_display": "Medicare/Medicaid", "description": "Issues related to policy changes to Medicare Part D.", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 56443, "prefix": null, "prefix_display": null, "first_name": "RICK", "nickname": null, "middle_name": null, "last_name": "DESIMONE", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "MED", "general_issue_code_display": "Medical/Disease Research/Clinical Labs", "description": "Issues related to access to medicines and other medical therapies, the development of new medical therapies, pharmaceutical supply chain and regulatory matters regarding the biopharmaceutical industry.", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 56443, "prefix": null, "prefix_display": null, "first_name": "RICK", "nickname": null, "middle_name": null, "last_name": "DESIMONE", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "SCI", "general_issue_code_display": "Science/Technology", "description": "Issues related to the development of new medical therapies including patient access and pricing.", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 56443, "prefix": null, "prefix_display": null, "first_name": "RICK", "nickname": null, "middle_name": null, "last_name": "DESIMONE", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}], "conviction_disclosures": [], "foreign_entities": [], "affiliated_organizations": []} | WA | US | DC | US | US | trade group representing U.S. pharmaceutical research and biotechnology companies | 0 | 0 | 60000.0 |